loader from loading.io
Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit show art Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16)

info_outline
Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress show art Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

Research To Practice | Oncology Videos

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20)

info_outline
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy show art Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy

Research To Practice | Oncology Videos

Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05)

info_outline
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty Lecture) show art Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31)

info_outline
Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates show art Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

Research To Practice | Oncology Videos

Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib...

info_outline
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies show art Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies

Research To Practice | Oncology Videos

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration...

info_outline
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit show art EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics: Introduction (0:00) Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42) Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25)

info_outline
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit show art HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O’Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15)

info_outline
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2 show art Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2

Research To Practice | Oncology Videos

Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and...

info_outline
Ovarian Cancer — Proceedings from a Session Held During the 2025 SGO Annual Meeting on Women’s Cancer® show art Ovarian Cancer — Proceedings from a Session Held During the 2025 SGO Annual Meeting on Women’s Cancer®

Research To Practice | Oncology Videos

Featuring perspectives from Dr Kathleen N Moore, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Shannon N Westin, moderated by Dr Secord, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Westin (2:42) Management of Relapsed/Refractory OC — Dr Secord (23:06) Novel Investigational Therapies for Advanced OC — Dr Moore (46:55) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Salani (1:08:34)

info_outline
 
More Episodes

Featuring an interview with Dr Adrienne G Waks, including the following topics:

  • The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00)
  • Role of immunotherapy in the treatment of breast cancer (8:30)
  • Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55)
  • Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37)
  • Current role of anthracyclines in the treatment of localized breast cancer (31:17)
  • Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21)
  • Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53)

CME information and select publications